{"product_id":"cjc-1295-dac","title":"CJC-1295 + DAC","description":"\u003ch1 class=\"wp-block-heading\"\u003eCJC-1295 With DAC\u003c\/h1\u003e\n\u003cp\u003e2026 Scientific and Regulatory Research Reference\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eU.S. Research Peptide Market | PubChem CID 91971820 | C₁₆₅H₂₆₉N₄₇O₄₆ | MW 3,647.2 g\/mol\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eNOT FDA-APPROVED FOR ANY INDICATION — FOR EDUCATIONAL AND PROFESSIONAL REFERENCE ONLY\u003c\/p\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\u003c\/figure\u003e\n\u003ch2 class=\"wp-block-heading\"\u003e⚠ REGULATORY STATUS – READ BEFORE PROCEEDING\u003c\/h2\u003e\n\u003cblockquote\u003eREGULATORY DISCLOSURE: CJC-1295 With DAC is NOT FDA-APPROVED for any human therapeutic indication as of June 2026. No NDA, BLA, ANDA, or biologics license exists for CJC-1295 DAC or any of its salt forms (free base, acetate, trifluoroacetate).\u003c\/blockquote\u003e\n\u003cblockquote\u003ePCAC STATUS: At the December 4, 2024 Pharmacy Compounding Advisory Committee meeting, the FDA proposed that NONE of the CJC-1295 bulk drug substance variants (including DAC free base, DAC acetate, DAC trifluoroacetate) be placed on the 503A bulks list. The committee voted 0 yes \/ 13 no \/ 0 abstentions against inclusion.\u003c\/blockquote\u003e\n\u003cblockquote\u003e2026 RECLASSIFICATION: On February 27, 2026, HHS Secretary Kennedy directed the FDA to administratively reclassify approximately 14 restricted peptides including CJC-1295 from Category 2 back to Category 1 of the interim 503A bulks framework. This is NOT an FDA approval. It is an interim enforcement discretion measure. The compound remains unapproved and unvalidated for safety or efficacy. WADA: CJC-1295 is classified as a prohibited growth hormone-releasing factor analog under\u003c\/blockquote\u003e\n\u003cblockquote\u003eWADA Section S2. Athletes subject to anti-doping programs who use this substance risk sanctions regardless of its regulatory category status.\u003c\/blockquote\u003e\n\u003cblockquote\u003eThis document is a scientific and regulatory reference for educational, academic, and professional use only. No personal-use protocol, schedule, preparation instruction, or consumer self-use guidance is contained or implied herein.\u003c\/blockquote\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eProduct Overview\u003c\/h2\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eCJC-1295 with DAC is a long-acting synthetic analog of human growth hormone-releasing hormone (GHRH), engineered by ConjuChem Biotechnologies to overcome the primary limitation of native GHRH: rapid plasma degradation. Where endogenous GHRH is cleared within minutes, CJC-1295 with DAC achieves an estimated human terminal half-life of 5.8 to 8.1 days through a proprietary Drug Affinity Complex (DAC) that covalently conjugates the peptide to circulating serum albumin via a maleimide-thioether bond at Cys34.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003ePubChem records the compound under CID 91971820 with molecular formula C165H269N47O46 and a molecular weight of approximately 3,647.2 g\/mol. CAS Registry 446262-90-4 is most frequently cited for the DAC variant, though CAS 863288-34-0 appears in some vendor documents and refers more strictly to the non-DAC backbone. These nomenclature ambiguities represent a persistent quality-control risk in the gray market that researchers and compliance officers must actively manage.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003ePhase I trials (Teichman et al., 2006, JCEM) demonstrated that single study exposures of 30-60 mcg\/kg produced 2- to 10-fold increases in mean plasma GH sustained for at least 6 days, and 1.5- to 3-fold increases in IGF-1 for 9 to 11 days, with preserved pulsatile GH secretion architecture. A Phase II trial was halted in July 2006 following a participant death attributed to underlying coronary artery disease; the program was subsequently terminated, and the compound never advanced to Phase III or NDA submission.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe 2026 regulatory environment for CJC-1295 with DAC is uniquely dynamic. Following the December 2024 PCAC vote against its inclusion on the 503A bulks list, the HHS Secretary issued a directive in February 2026 to reclassify CJC-1295 among other peptides to Category 1. This does not change its unapproved status but temporarily restores a pathway for licensed 503A compounding with valid physician prescriptions, pending formal review. The July 23-24, 2026 PCAC meeting represents the next critical regulatory inflection point.\u003c\/p\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eCHEMICAL IDENTITY — PubChem, CAS, AND MOLECULAR ARCHITECTURE\u003c\/h2\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eCanonical Database Identifiers\u003c\/h3\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable height=\"347\" style=\"width: 90.6404%;\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth style=\"width: 19.9005%;\"\u003eIdentifier\u003c\/th\u003e\n\u003cth style=\"width: 46.6003%;\"\u003eCJC-1295 WITH DAC\u003c\/th\u003e\n\u003cth style=\"width: 33.0017%;\"\u003eCJC-1295 WITHOUT DAC (Mod GRF 1-29)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 19.9005%;\"\u003ePubChem CID\u003c\/td\u003e\n\u003ctd style=\"width: 46.6003%;\"\u003e91971820\u003c\/td\u003e\n\u003ctd style=\"width: 33.0017%;\"\u003e56841945\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 19.9005%;\"\u003eCAS Registry Number\u003c\/td\u003e\n\u003ctd style=\"width: 46.6003%;\"\u003e446262-90-4 (primary)\u003c\/td\u003e\n\u003ctd style=\"width: 33.0017%;\"\u003e863288-34-0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 19.9005%;\"\u003eMolecular Formula\u003c\/td\u003e\n\u003ctd style=\"width: 46.6003%;\"\u003eC165H269N47O46\u003c\/td\u003e\n\u003ctd style=\"width: 33.0017%;\"\u003eC152H252N44O42\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 19.9005%;\"\u003eMolecular Weight\u003c\/td\u003e\n\u003ctd style=\"width: 46.6003%;\"\u003e3,647.2 g\/mol (computed)\u003c\/td\u003e\n\u003ctd style=\"width: 33.0017%;\"\u003e3,367.9 g\/mol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 19.9005%;\"\u003eIUPAC Nomenclature\u003c\/td\u003e\n\u003ctd style=\"width: 46.6003%;\"\u003eN-epsilon30-maleimidopropionyl-[D-Ala2,Gln8,Ala15,Leu27]-Sermorelin-Lys30\u003c\/td\u003e\n\u003ctd style=\"width: 33.0017%;\"\u003e[D-Ala2,Gln8,Ala15,Leu27]-Sermorelin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 19.9005%;\"\u003eEstimated Human Half-Life\u003c\/td\u003e\n\u003ctd style=\"width: 46.6003%;\"\u003e5.8 – 8.1 days (albumin-bound)\u003c\/td\u003e\n\u003ctd style=\"width: 33.0017%;\"\u003e~30 minutes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 19.9005%;\"\u003eClearance Mechanism\u003c\/td\u003e\n\u003ctd style=\"width: 46.6003%;\"\u003eCovalent albumin bioconjugation via Cys34 thioether bond\u003c\/td\u003e\n\u003ctd style=\"width: 33.0017%;\"\u003eEnzymatic (DPP-IV) and renal clearance\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 19.9005%;\"\u003eAmino Acid Length\u003c\/td\u003e\n\u003ctd style=\"width: 46.6003%;\"\u003e30 amino acids (29-aa hGRF backbone + DAC linker-Lys30)\u003c\/td\u003e\n\u003ctd style=\"width: 33.0017%;\"\u003e29 amino acids\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eThe GHRH(1-29) Backbone and Tetrasubstitution\u003c\/h3\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eNative human growth hormone-releasing hormone (hGHRH) is a 44-amino-acid peptide synthesized in the arcuate nucleus of the hypothalamus. Its receptor-binding activity is fully retained within the first 29 amino acids, a truncated sequence known as GHRH(1-29) or Sermorelin. However, native GHRH(1-29) is rapidly cleaved by dipeptidyl peptidase-4 (DPP-IV), which attacks the peptide bond between positions 2 and 3, yielding an in vivo half-life of fewer than 7 minutes and making it impractical as a long-acting research tool.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eConjuChem Biotechnologies addressed this limitation by introducing four targeted amino acid substitutions into the GHRH(1-29) backbone: D-Alanine at position 2 (primary DPP-IV resistance), Glutamine at position 8, Alanine at position 15, and Leucine at position 27. These modifications confer marked resistance to proteolytic degradation while preserving high-affinity binding at the GHRH receptor on anterior pituitary somatotrophs. The resulting backbone is referred to in literature as Modified GRF 1-29 (Mod GRF 1-29) and constitutes the structural foundation of both DAC and non-DAC CJC-1295 variants.\u003c\/p\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eThe DAC Modification: Maleimidopropionyl-Lysine and In Vivo Bioconjugation\u003c\/h3\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe defining structural feature of CJC-1295 with DAC is the C-terminal extension incorporating a lysine residue conjugated to a maleimidopropionyl group (N-epsilon-maleimidopropionyl-Lysine at position 30). This Drug Affinity Complex (DAC) was explicitly engineered to react with the free thiol group of cysteine-34 (Cys34) located on circulating human serum albumin, the most abundant plasma protein in human blood.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eIn published pharmacokinetic studies, the maleimide group undergoes a rapid, spontaneous, and irreversible Michael addition with the Cys34 thiol, forming a stable thioether bond. This covalent bioconjugation creates a macromolecular peptide-albumin complex that exploits albumin’s natural long half-life (approximately 19 days) and protection from renal clearance, extending the functional pharmacokinetic profile of CJC-1295 from minutes to days. The result is a circulating complex that maintains GHRH receptor binding affinity across an extended pharmacodynamic window.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eANALYTICAL VERIFICATION NOTE FOR RESEARCH PROCUREMENT\u003c\/strong\u003e\u003c\/p\u003e\n\u003cblockquote\u003e\n\u003cp\u003eBecause CJC-1295 with DAC and CJC-1295 without DAC share the same hGRF(1-29) backbone but differ critically in the C-terminal DAC maleimido-lysine extension, their molecular masses are definitively different: 3,647 Da (with DAC) vs. 3,368 Da (without DAC). LC-MS analysis is the gold standard for confirmation.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eIf LC-MS of a batch labeled “CJC-1295 DAC” returns a mass of approximately 3,368 Da rather than 3,647 Da, the supplier has provided the non-DAC variant. This represents a severe supply chain integrity failure that would invalidate longitudinal pharmacokinetic research protocols.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003ePubChem CID 91971820 | pubchem.ncbi.nlm.nih.gov\/compound\/91971820\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eMECHANISM OF ACTION — GHRH RECEPTOR PHARMACOLOGY AND ENDOCRINE CASCADE\u003c\/h2\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eGHRH Receptor Agonism and Intracellular Signaling Cascade\u003c\/h3\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSignaling Step\u003c\/th\u003e\n\u003cth\u003eBiochemical Event\u003c\/th\u003e\n\u003cth\u003eDownstream Effect\u003c\/th\u003e\n\u003cth\u003eResearch Source\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStep 1 – Receptor Binding\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 DAC (albumin-bound complex) binds GHRH receptor (GHRHR) on anterior pituitary somatotroph cells. GHRHR is a Gs-protein-coupled receptor (GPCR).\u003c\/td\u003e\n\u003ctd\u003eReceptor occupancy triggers Gs-alpha subunit activation and dissociation\u003c\/td\u003e\n\u003ctd\u003eTeichman et al., 2006 JCEM; PubChem CID 91971820\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStep 2 – Adenylate Cyclase Activation\u003c\/td\u003e\n\u003ctd\u003eActivated Gs-alpha stimulates adenylate cyclase, catalyzing conversion of ATP to cAMP. Intracellular cAMP concentrations rise rapidly within somatotrophs.\u003c\/td\u003e\n\u003ctd\u003eElevated intracellular cAMP serves as second messenger for PKA activation\u003c\/td\u003e\n\u003ctd\u003eConjuChem MOA documents; Ionescu et al., pulsatility research\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStep 3 – PKA Activation\u003c\/td\u003e\n\u003ctd\u003ecAMP activates Protein Kinase A (PKA). PKA phosphorylates downstream targets including cAMP-response element binding protein (CREB) and voltage-gated Ca2+ channels.\u003c\/td\u003e\n\u003ctd\u003eCa2+ channel opening increases intracellular calcium; CREB drives GH gene transcription\u003c\/td\u003e\n\u003ctd\u003eTeichman et al., 2006; ProPeptideGuide MOA review\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStep 4 – GH Synthesis and Exocytosis\u003c\/td\u003e\n\u003ctd\u003eElevated intracellular Ca2+ triggers exocytosis of pre-synthesized GH-containing secretory granules. Simultaneously, CREB activation upregulates GH gene expression, expanding the releasable GH pool.\u003c\/td\u003e\n\u003ctd\u003eGrowth hormone is released into systemic circulation in pulses superimposed on a raised trough baseline\u003c\/td\u003e\n\u003ctd\u003eTeichman et al., 2006; Phase I ascending-dose trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStep 5 – IGF-1 Axis Activation\u003c\/td\u003e\n\u003ctd\u003eElevated circulating GH acts on hepatic (liver) GH receptors, stimulating synthesis and secretion of Insulin-like Growth Factor 1 (IGF-1). Peripheral tissues also produce IGF-1 in response to GH signaling.\u003c\/td\u003e\n\u003ctd\u003eIGF-1 mediates anabolic, proliferative, and tissue-remodeling effects attributed to GH axis activation\u003c\/td\u003e\n\u003ctd\u003eTeichman 2006; FDA PCAC briefing Dec 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eContinuous vs. Pulsatile Stimulation: The Critical Pharmacokinetic Paradigm\u003c\/h3\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe endocrine significance of CJC-1295 with DAC lies in a fundamental pharmacokinetic differentiation from both native GHRH and short-acting analogs. Endogenous GH secretion is strictly pulsatile: the hypothalamus releases GHRH in discrete bursts, primarily during slow-wave sleep stages, producing approximately 6-12 GH pulses per day in healthy adults, with low trough concentrations between pulses.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eCJC-1295 without DAC (Mod GRF 1-29), with its approximately 30-minute half-life, largely mirrors this physiological pulsatility when administered: it triggers a discrete, amplified GH pulse before rapid clearance allows the system to return to baseline, preserving normal receptor cycling dynamics.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eCJC-1295 with DAC fundamentally disrupts this architecture. Its 5.8-8.1 day half-life maintains near-constant GHRH receptor occupancy, producing tonically elevated GH trough and mean concentrations across the entire diurnal cycle. Critically, Ionescu and colleagues demonstrated that despite this continuous stimulation, pulsatile GH secretion is largely preserved above the elevated baseline rather than abolished – the pituitary still fires GH pulses, but from a significantly higher starting concentration. This tonic elevation paradigm is precisely the feature that enables weekly or biweekly research regimens in pharmacological studies while simultaneously raising FDA concerns regarding immunogenicity and non-physiological chronic endocrine stress.\u003c\/p\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eHUMAN PHARMACOKINETICS AND PHARMACODYNAMICS — TEICHMAN 2006 PHASE I DATA\u003c\/h2\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe definitive human pharmacological and safety dataset for CJC-1295 with DAC derives from the landmark 2006 Phase I randomized, double-blind, placebo-controlled, ascending-dose trials conducted by Teichman et al. and published in the Journal of Clinical Endocrinology and Metabolism. These remain the most cited and rigorously controlled human data for this compound as of June 2026.\u003c\/p\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eParameter\u003c\/th\u003e\n\u003cth\u003eData from Teichman et al. 2006 Phase I Trial\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudy Design\u003c\/td\u003e\n\u003ctd\u003eRandomized, double-blind, placebo-controlled, ascending-dose Phase I trial in healthy adult volunteers (two companion studies)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses Tested\u003c\/td\u003e\n\u003ctd\u003eSingle study exposures at 30 mcg\/kg and 60 mcg\/kg body weight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGH Response\u003c\/td\u003e\n\u003ctd\u003e2- to 10-fold increase in mean plasma GH concentration sustained for at least 6 days following a single injection. Effect was dose-dependent.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGF-1 Response\u003c\/td\u003e\n\u003ctd\u003e1.5- to 3-fold increase in mean plasma IGF-1 concentration sustained for 9-11 days following a single injection. Multiple weekly\/biweekly doses sustained IGF-1 elevation for up to 28 days.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTerminal Half-Life\u003c\/td\u003e\n\u003ctd\u003eEstimated at 5.8-8.1 days. Cumulative effect observed with repeated research regimens at weekly or biweekly intervals.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGH Pulsatility\u003c\/td\u003e\n\u003ctd\u003ePulsatile GH secretion architecture was largely preserved above the elevated trough baseline (confirmed in companion Ionescu et al. study). Endogenous pulse frequency and amplitude persisted superimposed on raised mean\/trough levels.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdverse Events\u003c\/td\u003e\n\u003ctd\u003eMild to moderate injection-site reactions (erythema, induration), transient facial flushing and warmth (vasodilatory, reflecting vascular GHRH receptor expression), mild fluid retention\/edema secondary to GH-induced aldosterone effects, and transient flu-like symptoms. No serious acute adverse events in Phase I cohort.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLimitations\u003c\/td\u003e\n\u003ctd\u003eSmall sample sizes; short observation windows; healthy adult cohort only; no long-duration safety\/efficacy endpoints; no diverse population data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eCOMPARISON WITH TESAMORELIN (FDA-APPROVED GHRH ANALOG)\u003c\/h2\u003e\n\u003cp class=\"wp-block-paragraph\"\u003ePubChem CID 91971820 — CJC-1295 With DAC (Drug Affinity Complex) molecular structure — C165H269N47O46 — MW 3647.2 g\/mol — 30-residue GHRH analog with maleimidopropionyl albumin-binding DAC modification — CAS 446262-90-4 — NIH PubChem 2026\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eTesamorelin (Egrifta SV) is the only FDA-approved GHRH analog as of June 2026, approved specifically for reducing excess abdominal fat in HIV-positive adults with lipodystrophy. CJC-1295 with DAC should never be represented as equivalent to or interchangeable with tesamorelin.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eKey distinctions: Tesamorelin completed Phase III trials with a statistically significant primary endpoint (visceral fat reduction vs. placebo) and received NDA approval (NDA 022505). CJC-1295 with DAC was halted at Phase II, never submitted an NDA, and remains unapproved. Their pharmacokinetic profiles, approved indications, and regulatory standings are entirely distinct.\u003c\/p\u003e\n\u003ch3\u003eMolecular structure :\u003c\/h3\u003e\n\u003cfigure id=\"attachment_221879\" class=\"wp-caption aligncenter\"\u003e\u003cimg data-attachment-id=\"221879\" data-permalink=\"https:\/\/profoundaminos.com\/?attachment_id=221879\" data-orig-file=\"https:\/\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820.webp\" data-orig-size=\"1024,1024\" data-comments-opened=\"1\" data-image-meta='{\"aperture\":\"0\",\"credit\":\"\",\"camera\":\"\",\"caption\":\"\",\"created_timestamp\":\"0\",\"copyright\":\"\",\"focal_length\":\"0\",\"iso\":\"0\",\"shutter_speed\":\"0\",\"title\":\"\",\"orientation\":\"0\",\"alt\":\"\"}' data-image-title=\"CJC-1295 With DAC Molecular Structure PubChem CID 91971820\" data-image-description=\"\u0026lt;p\u0026gt;This image shows the molecular structure of CJC-1295 With DAC, a long-acting synthetic GHRH analog registered in PubChem under CID 91971820. The compound includes a Drug Affinity Complex modification designed to support albumin binding and extended pharmacokinetic behavior in research models. CJC-1295 With DAC has the molecular formula C₁₆₅H₂₆₉N₄₇O₄₆ and molecular weight of approximately 3,647.2 g\/mol. This visual is intended for scientific, educational, and regulatory reference content only.\u0026lt;\/p\u0026gt;\" data-image-caption=\"\u0026lt;p\u0026gt;CJC-1295 With DAC molecular structure, representing the long-acting GHRH receptor agonist with DAC albumin-binding modification. PubChem CID 91971820 | C₁₆₅H₂₆₉N₄₇O₄₆ | MW 3,647.2 g\/mol.\u0026lt;\/p\u0026gt;\" data-large-file=\"https:\/\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820.webp\" alt=\"CJC-1295 With DAC molecular structure showing the long-acting GHRH analog with Drug Affinity Complex modification, PubChem CID 91971820.\" width=\"415\" height=\"415\" sizes=\"auto, (max-width: 415px) 100vw, 415px\" class=\"wp-image-221879 lazyloaded\" decoding=\"async\" id=\"MjUzMToxNDI4-1\" data-nitro-empty-id=\"MjUzMToxNDI4-1\" src=\"https:\/\/cdn-iledacd.nitrocdn.com\/SjFAtUDKoxpKJBWpudFZVunbmeIDeGio\/assets\/images\/optimized\/rev-14f178c\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820.webp\" srcset=\"https:\/\/cdn-iledacd.nitrocdn.com\/SjFAtUDKoxpKJBWpudFZVunbmeIDeGio\/assets\/images\/optimized\/rev-14f178c\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820.webp 1024w, https:\/\/cdn-iledacd.nitrocdn.com\/SjFAtUDKoxpKJBWpudFZVunbmeIDeGio\/assets\/images\/optimized\/rev-14f178c\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820-300x300.webp 300w, https:\/\/cdn-iledacd.nitrocdn.com\/SjFAtUDKoxpKJBWpudFZVunbmeIDeGio\/assets\/images\/optimized\/rev-14f178c\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820-150x150.webp 150w, https:\/\/cdn-iledacd.nitrocdn.com\/SjFAtUDKoxpKJBWpudFZVunbmeIDeGio\/assets\/images\/optimized\/rev-14f178c\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820-768x768.webp 768w, https:\/\/cdn-iledacd.nitrocdn.com\/SjFAtUDKoxpKJBWpudFZVunbmeIDeGio\/assets\/images\/optimized\/rev-14f178c\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820-700x700.webp 700w, https:\/\/cdn-iledacd.nitrocdn.com\/SjFAtUDKoxpKJBWpudFZVunbmeIDeGio\/assets\/images\/optimized\/rev-14f178c\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820-500x500.webp 500w, https:\/\/cdn-iledacd.nitrocdn.com\/SjFAtUDKoxpKJBWpudFZVunbmeIDeGio\/assets\/images\/optimized\/rev-14f178c\/profoundaminos.com\/wp-content\/uploads\/2025\/02\/CJC-1295-With-DAC-Molecular-Structure-PubChem-CID-91971820-100x100.webp 100w\"\u003e\n\u003cfigcaption id=\"caption-attachment-221879\" class=\"wp-caption-text\"\u003eCJC-1295 With DAC molecular structure, representing the long-acting GHRH receptor agonist with DAC albumin-binding modification. PubChem CID 91971820 | C₁₆₅H₂₆₉N₄₇O₄₆ | MW 3,647.2 g\/mol.\u003c\/figcaption\u003e\n\u003c\/figure\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eCLINICAL TRIAL HISTORY — PHASE II DISCONTINUATION AND SAFETY RECORD\u003c\/h2\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eThe Phase II Lipodystrophy Trial and Program Termination\u003c\/h3\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eFollowing published Phase I pharmacokinetic work, ConjuChem Biotechnologies ran a Phase II study (ClinicalTrials.gov: NCT00267527) evaluating CJC-1295 with DAC in a multicenter, randomized, placebo-controlled clinical-research protocol. Public study records describe enrollment of 192 participants across North and South American sites. Those materials are literature\/regulatory context only and do not imply approved use, personal-use directions, or outcomes for this RUO listing.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eIn July 2006, the trial was abruptly halted following the death of a participant at a clinical site in Argentina. The patient experienced an acute myocardial infarction approximately two hours after receiving their 11th consecutive weekly dose. Investigation attributed the event to underlying, asymptomatic coronary artery disease with acute plaque rupture and vascular occlusion. The official medical consensus recorded the death as coincidental rather than directly caused by CJC-1295 pharmacology.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eNevertheless, ConjuChem placed the program on clinical hold and subsequently made the strategic decision to terminate development entirely. The compound never advanced to Phase III, never submitted an NDA, and has remained in clinical dormancy within the formal pharmaceutical sector since 2006. This termination history is directly relevant to FDA’s regulatory posture: the agency explicitly cited the Phase II death, alongside unresolved immunogenicity concerns and insufficient long-term safety data, in its PCAC briefing materials against 503A inclusion.\u003c\/p\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eFDA Safety Concerns Documented in PCAC Briefing Materials (December 2024)\u003c\/h3\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eSafety Domain\u003c\/th\u003e\n\u003cth\u003eFDA Concern as Documented in December 4, 2024 PCAC Briefing Package\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunogenicity\u003c\/td\u003e\n\u003ctd\u003eThe DAC modification creates a novel bioconjugate not found in nature. FDA views the peptide-albumin complex as presenting elevated immunogenic risk, potentially triggering immune recognition of the conjugate as a foreign antigen. Reactions could range from injection-site hypersensitivity to systemic anaphylaxis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular Events\u003c\/td\u003e\n\u003ctd\u003eGHRH analogs produce vasodilation via vascular GHRH receptor expression. FDA cites the Phase II participant death, known hemodynamic effects (elevated heart rate, transient hypotension, facial flushing), and theoretical GH-mediated cardiovascular stress from chronic IGF-1 elevation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncological Risk\u003c\/td\u003e\n\u003ctd\u003eSustained, non-physiological GH\/IGF-1 elevation inhibits apoptosis and promotes cellular proliferation. While CJC-1295 is not proven to initiate de novo tumorigenesis, continuous IGF-1 elevation is contraindicated in individuals with active malignancies or high cancer risk profiles.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMC and Quality\u003c\/td\u003e\n\u003ctd\u003eFDA cited incomplete chemistry, manufacturing, and controls (CMC) data for bulk CJC-1295 materials. Impurities, endotoxin levels, and quality consistency of gray-market API sources were specifically flagged as significant concerns.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsufficient Evidence\u003c\/td\u003e\n\u003ctd\u003eNo large, long-duration randomized controlled trials tracking cardiovascular, oncological, or mortality endpoints exist. The only human data derives from small, short-term Phase I trials in healthy adults and one halted Phase II study.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eU.S. REGULATORY LANDSCAPE — 2024 PCAC, 2026 RECLASSIFICATION, AND ENFORCEMENT\u003c\/h2\u003e\n\u003ch3 class=\"wp-block-heading\"\u003e503A Compounding Framework and the Category System\u003c\/h3\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eUnder Section 503A of the Federal Food, Drug, and Cosmetic Act (FD\u0026amp;C Act), as enacted by the Drug Quality and Security Act (DQSA) of 2013, a state-licensed compounding pharmacy may use a bulk drug substance in a compounded preparation only if: (1) it has an applicable USP\/NF monograph; (2) it is a component of an FDA-approved drug; or (3) it appears explicitly on the FDA’s 503A Bulks List of approved bulk substances. CJC-1295 satisfies none of the first two criteria, making 503A Bulks List inclusion its only legal pathway to medical compounding for human use.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe FDA established an interim categorization system to manage the large volume of industry nominations for unapproved peptides. Category 1 contains substances under active review that compounders may produce pending evaluation. Category 2 identifies substances presenting significant safety risks where compounding is effectively prohibited and exposes pharmacies to enforcement liability. Category 3 contains substances with insufficient data for evaluation.\u003c\/p\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eRegulatory Timeline: CJC-1295 with DAC (2023-2026)\u003c\/h3\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable height=\"788\" style=\"width: 100%;\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth style=\"width: 12.1023%;\"\u003eDate\u003c\/th\u003e\n\u003cth style=\"width: 18.3113%;\"\u003eEvent\u003c\/th\u003e\n\u003cth style=\"width: 65.9739%;\"\u003eRegulatory Detail and Market Impact\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 12.1023%;\"\u003eLate 2023\u003c\/td\u003e\n\u003ctd style=\"width: 18.3113%;\"\u003eCategory 2 Placement\u003c\/td\u003e\n\u003ctd style=\"width: 65.9739%;\"\u003eFDA placed 19 peptides including CJC-1295 (all variants) into Category 2 of the interim 503A bulks list, citing immunogenicity, lack of Phase III data, and CMC quality concerns. Licensed compounding pharmacies could no longer legally prepare CJC-1295 for human use under 503A. Gray-market gray market volume surged.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 12.1023%;\"\u003eSeptember 27, 2024\u003c\/td\u003e\n\u003ctd style=\"width: 18.3113%;\"\u003eRemoval from Cat. 2\u003c\/td\u003e\n\u003ctd style=\"width: 65.9739%;\"\u003eFDA announced removal of CJC-1295 (along with AOD-9604, ipamorelin acetate, thymosin alpha-1, and Selank acetate) from Category 2, not as an approval, but because original nominators withdrew their petitions. FDA indicated it would bring CJC-1295 to PCAC for a dedicated, FDA-initiated evaluation.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 12.1023%;\"\u003eDecember 4, 2024\u003c\/td\u003e\n\u003ctd style=\"width: 18.3113%;\"\u003ePCAC Vote: 0-13-0\u003c\/td\u003e\n\u003ctd style=\"width: 65.9739%;\"\u003eFDA presented a detailed briefing proposing that NONE of the CJC-1295 bulk substance variants (free base, acetate, DAC free base, DAC acetate, DAC trifluoroacetate) be placed on the 503A bulks list. The PCAC voted 0 yes \/ 13 no \/ 0 abstentions for each DAC variant. This definitive rejection solidified FDA’s “do not compound” posture for all CJC-1295 salt forms.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 12.1023%;\"\u003eFebruary 27, 2026\u003c\/td\u003e\n\u003ctd style=\"width: 18.3113%;\"\u003eHHS Category 1 Reclassification\u003c\/td\u003e\n\u003ctd style=\"width: 65.9739%;\"\u003eHHS Secretary Kennedy directed FDA to administratively reclassify approximately 14 restricted peptides including CJC-1295 from Category 2 back to Category 1 of the interim 503A framework. This is an interim enforcement discretion measure – NOT an FDA approval, NOT a safety validation, and NOT a reversal of the December 2024 PCAC vote. Licensed 503A pharmacies may now prepare CJC-1295 with valid physician prescriptions pending formal review.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 12.1023%;\"\u003eApril 2026\u003c\/td\u003e\n\u003ctd style=\"width: 18.3113%;\"\u003eCategory 1 Effective; Enforcement Context\u003c\/td\u003e\n\u003ctd style=\"width: 65.9739%;\"\u003eReclassification reported as taking effect in late April 2026. Compounding pharmacies began rebuilding CJC-1295 supply chains. FDA enforcement campaigns (30 warning letters in March 2026; 25 in the week of June 15, 2026) continued targeting telehealth platforms making misleading claims about compounded peptide products.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 12.1023%;\"\u003eJuly 23-24, 2026\u003c\/td\u003e\n\u003ctd style=\"width: 18.3113%;\"\u003ePCAC Meeting (Pending)\u003c\/td\u003e\n\u003ctd style=\"width: 65.9739%;\"\u003eScheduled PCAC meeting formally evaluates BPC-157, KPV, TB-500, MOTS-c (Day 1) and DSIP, Semax, Epitalon (Day 2) for 503A inclusion. While CJC-1295 is not on the published agenda, the outcomes will signal FDA’s longer-term regulatory posture for the entire peptide compounding category and the HHS mandate’s durability. The meeting represents the next critical bellwether for the U.S. peptide market.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003cp\u003e\u003cstrong\u003eCRITICAL COMPLIANCE DISTINCTION: CATEGORY 1 IS NOT FDA APPROVAL\u003c\/strong\u003e\u003c\/p\u003e\n\u003cblockquote\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe February 2026 HHS reclassification of CJC-1295 to Category 1 is an administrative enforcement discretion measure only. It does not constitute:\u003c\/p\u003e\n\u003cul class=\"wp-block-list\"\u003e\n\u003cli\u003eFDA approval for any therapeutic indication\u003c\/li\u003e\n\u003cli\u003eA reversal of the December 4, 2024 PCAC vote (0-13-0 against 503A inclusion)\u003c\/li\u003e\n\u003cli\u003eValidation of safety or clinical efficacy for any condition\u003c\/li\u003e\n\u003cli\u003eAuthorization for 503B outsourcing facilities to bulk-produce the compound\u003c\/li\u003e\n\u003cli\u003ePermission to make outcome claims, use finished-drug language, or present this compound as an approved product for use in humans or animals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"wp-block-paragraph\"\u003ePhysicians prescribing CJC-1295 under Category 1 must implement rigorous informed consent protocols explicitly disclosing: (1) unapproved status; (2) unresolved long-term safety questions; (3) cardiovascular and immunogenicity concerns documented in FDA PCAC briefings.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eFDA ENFORCEMENT CAMPAIGNS — 2025 AND 2026\u003c\/h2\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe FDA significantly escalated enforcement activity against the peptide gray market throughout 2025 and 2026, demonstrating a willingness to prosecute beyond traditional compounding pharmacies to include online RUO vendors and telehealth platforms. The legal framework deployed centers on Sections 301, 502(a), and 502(n) of the FDCA, targeting misbranding (misleading net impression of approval) and introduction of unapproved new drugs into interstate commerce.\u003c\/p\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eKey Enforcement Actions and Legal Framework\u003c\/h3\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eEnforcement Action\u003c\/th\u003e\n\u003cth\u003eDetail and Compliance Implication\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUSApeptide.com Warning Letter (February 26, 2025)\u003c\/td\u003e\n\u003ctd\u003eMARCS-CMS 696885. FDA CDER cited introduction of misbranded and unapproved new drugs into interstate commerce. Explicitly stated that “Research Use Only” disclaimers do not circumvent FDCA Sections 301 and 503 when the totality of marketing implies intended use in humans. Regimen calculators, human outcome-claim language, and bundling with Solution on vendor websites were cited as evidence of that intent.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarch 2026: 30-Letter Wave to Telehealth Firms\u003c\/td\u003e\n\u003ctd\u003eCoordinated enforcement targeting telehealth companies making misleading claims about compounded GLP-1 analogs and longevity peptides. Citations focused on FDCA Sections 502(a) and 502(n) misbranding – specifically, creating a “misleading net impression” that compounded products are FDA-approved, equivalent to branded drugs, or produced at “FDA-approved pharmacies.”\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJune 15, 2026: 25-Letter Wave\u003c\/td\u003e\n\u003ctd\u003eAdditional round of 25 warning letters to telehealth firms and online peptide vendors. FDA launched a dedicated telehealth compliance webpage. Frier Levitt and Sheppard law analyses confirm expanding scope of enforcement beyond GLP-1 products to include longevity and optimization peptides broadly.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThe RUO Shield Fallacy\u003c\/td\u003e\n\u003ctd\u003e“Research Use Only” labeling does not provide legal immunity when the totality of marketing context indicates intended use in humans. FDA evaluates: presence of regimen or quantity guidance, human outcome testimonials, finished-drug language, bundling with administration supplies, and consumer testimonial reviews. When these indicators are present, FDA regulates the product as an unapproved new drug regardless of label disclaimers.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eANTI-DOPING STATUS AND DETECTION SCIENCE — WADA 2026\u003c\/h2\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eCJC-1295 is explicitly prohibited under the World Anti-Doping Agency (WADA) Prohibited List as a growth hormone-releasing factor (GRF) analog, classified under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). This prohibition applies to all competitive athletes subject to WADA-compliant anti-doping programs, including Olympic, Paralympic, and most professional sports governing bodies worldwide.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eAnti-doping research has specifically targeted CJC-1295. A Drug Testing and Analysis study identified CJC-1295 as the active compound in an unknown peptide preparation used by athletes seeking GH-axis enhancement, confirming its real-world use as a GH-releasing factor in competitive sport contexts. Subsequent research developed immuno-polymerase chain reaction (immuno-PCR) detection methods capable of identifying CJC-1295 at very low plasma concentrations in equine samples, illustrating the sophistication of anti-doping surveillance for this compound. These analytical methods are applicable across human and equine testing matrices.\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe “Research Use Only” designation on commercial vials of CJC-1295 with DAC does not exempt athletes from WADA anti-doping sanctions. The substance itself is prohibited regardless of the stated purpose of procurement, the regulatory category it occupies in the U.S. compounding framework, or the manner in which it is labeled by the vendor. Any athlete subject to anti-doping regulations who tests positive for CJC-1295 faces sanctions consistent with the applicable sport’s governing body anti-doping policies.\u003c\/p\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eU.S. RESEARCH PEPTIDE MARKET CONTEXT — 2026 POSITIONING\u003c\/h2\u003e\n\u003ch3 class=\"wp-block-heading\"\u003eMarket Size and Commercial Dynamics\u003c\/h3\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable height=\"463\" style=\"width: 100%;\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth style=\"width: 18.7552%;\"\u003eMarket Metric\u003c\/th\u003e\n\u003cth style=\"width: 78.6176%;\"\u003e2026 Data and Analysis\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 18.7552%;\"\u003eGlobal Peptide Therapeutics Market\u003c\/td\u003e\n\u003ctd style=\"width: 78.6176%;\"\u003eEstimated USD 140.9 billion (2025); projected USD 164.0 billion (2026); CAGR 8.7% toward USD 294.6 billion by 2033 (Grand View Research; GMInsights)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 18.7552%;\"\u003eU.S. Gray\/Off-Label Peptide Market\u003c\/td\u003e\n\u003ctd style=\"width: 78.6176%;\"\u003eIndependent estimates suggest U.S. off-label and gray-market peptide revenue approaches USD 10 billion annually. Driven by longevity, body composition, recovery, and cognitive optimization demand.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 18.7552%;\"\u003eNorth America Market Share\u003c\/td\u003e\n\u003ctd style=\"width: 78.6176%;\"\u003eApproximately 61.9% of the global peptide therapeutics market (per third-party market analyses)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 18.7552%;\"\u003eGLP-1 Market Disruption Effect\u003c\/td\u003e\n\u003ctd style=\"width: 78.6176%;\"\u003eResolution of GLP-1-Sm \u003cspan\u003eshortage (February 2025) and \u003c\/span\u003e\u003cspan\u003eGLP\/GIP-Tz \u003c\/span\u003e\u003cspan\u003eshortage (December 2024) ended GLP-1 compounding window. Capitalized telehealth platforms pivoted aggressively toward longevity\/optimization peptides including CJC-1295, driving rapid regulatory blowback.\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 18.7552%;\"\u003eTelehealth Capital Consolidation\u003c\/td\u003e\n\u003ctd style=\"width: 78.6176%;\"\u003eHims \u0026amp; Hers acquired Australian platform Eucalyptus for USD 1.1 billion in 2026, concurrent with a Novo Nordisk patent infringement lawsuit over compounded GLP-1-Sm, illustrating the scale of capital in the compounded peptide\/GLP-1 sector.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd style=\"width: 18.7552%;\"\u003eCJC-1295 RUO Market Form\u003c\/td\u003e\n\u003ctd style=\"width: 78.6176%;\"\u003eCJC-1295 with DAC is commercially available as 5 mg lyophilized vials, purity \u0026gt;=98-99% by HPLC\/LC-MS, storage at -20C. Commonly offered alongside ipamorelin, GHRP-2\/6, and other GH secretagogues in research catalogs. PubChem CID 91971820 is the verified identity anchor.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch3 class=\"wp-block-heading\"\u003ePosition Relative to Other GH-Axis Research Agents\u003c\/h3\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAgent\u003c\/th\u003e\n\u003cth\u003eFDA Status\u003c\/th\u003e\n\u003cth\u003eKey Distinction from CJC-1295 DAC\u003c\/th\u003e\n\u003cth\u003eHalf-Life \/ Research regimen\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCJC-1295 with DAC (This Reference)\u003c\/td\u003e\n\u003ctd\u003eNOT approved. Category 1 (Feb 2026 reclassification). PCAC voted 0-13 against (Dec 2024).\u003c\/td\u003e\n\u003ctd\u003eLong-acting albumin-conjugated GHRHR agonist; 30-aa backbone + DAC linker; tonic GH\/IGF-1 elevation\u003c\/td\u003e\n\u003ctd\u003e5.8-8.1 days; weekly or biweekly research regimens\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCJC-1295 without DAC (Mod GRF 1-29)\u003c\/td\u003e\n\u003ctd\u003eNOT approved. Category status: under review.\u003c\/td\u003e\n\u003ctd\u003eSame tetrasubstituted backbone, no albumin-binding DAC. Short-acting; mimics physiological GH pulsatility. Different PubChem CID: 56841945.\u003c\/td\u003e\n\u003ctd\u003e~30 minutes; mimics physiological GH pulse timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTesamorelin (Egrifta SV)\u003c\/td\u003e\n\u003ctd\u003eFDA APPROVED. NDA 022505. Rx-only for HIV lipodystrophy only.\u003c\/td\u003e\n\u003ctd\u003eDistinct GHRH analog structure. Completed Phase III. ONLY FDA-approved GHRH analog. NOT interchangeable with CJC-1295 in research framing.\u003c\/td\u003e\n\u003ctd\u003eDaily SC injection; clinical protocol\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSermorelin\u003c\/td\u003e\n\u003ctd\u003ePreviously approved (withdrawn 2008). Compounding possible under 503A.\u003c\/td\u003e\n\u003ctd\u003eNative hGHRH(1-29) without substitutions. Short half-life. Different CAS and PubChem CID.\u003c\/td\u003e\n\u003ctd\u003eMinutes; daily\/twice-daily administration\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIpamorelin\u003c\/td\u003e\n\u003ctd\u003eNOT approved. Category 2 (Sept 2023); removed April 2026 for PCAC review. PCAC July 2026 agenda.\u003c\/td\u003e\n\u003ctd\u003eGHRP \/ ghrelin receptor agonist (GHS-R1a) – different receptor class from GHRH. Often used in experimental combination with CJC-1295 in research market.\u003c\/td\u003e\n\u003ctd\u003e~2 hours; complementary GH-pulse timing\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eQUALITY CONTROL AND ANALYTICAL COMPLIANCE STANDARDS — RESEARCH PROCUREMENT\u003c\/h2\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eFor academic institutions, contract research organizations (CROs), and legitimate biomedical laboratories using CJC-1295 with DAC strictly for in vitro or non-human research purposes, regulatory compliance requires rigorous analytical verification at the point of procurement. The gray market’s widespread mislabeling of CJC-1295 without DAC (MW ~3,368 Da) as the more expensive DAC variant (MW ~3,647 Da) represents a documented and pervasive research integrity risk.\u003c\/p\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAnalytical Test\u003c\/th\u003e\n\u003cth\u003eRequired Methodology\u003c\/th\u003e\n\u003cth\u003eSpecification for CJC-1295 DAC 5 mg\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChemical Identity Verification\u003c\/td\u003e\n\u003ctd\u003eLC-MS (Liquid Chromatography-Mass Spectrometry)\u003c\/td\u003e\n\u003ctd\u003eMonoisotopic mass ~3,647 Da. Definitively confirms presence of the DAC maleimido-lysine moiety. Mass of ~3,368 Da indicates non-DAC variant has been supplied.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeptide Purity\u003c\/td\u003e\n\u003ctd\u003eHPLC (High-Performance Liquid Chromatography)\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;=99.0% area under curve. Minimizes truncated peptide sequences, oxidized variants, and synthesis impurities that can invalidate cell-based assays.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Content \/ Yield\u003c\/td\u003e\n\u003ctd\u003eQuantitative assay (nitrogen content or HPLC calibration)\u003c\/td\u003e\n\u003ctd\u003e5.0 mg +\/- acceptable variance per lyophilized vial. Underfilling is common in gray-market sources.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndotoxin Contamination\u003c\/td\u003e\n\u003ctd\u003eUSP \u0026lt;85\u0026gt; (Limulus Amebocyte Lysate \/ LAL test)\u003c\/td\u003e\n\u003ctd\u003eMust pass established endotoxin limits. High endotoxin levels from bacterial fermentation contamination of API sources can produce false positive inflammatory responses in cell-based assays, invalidating biological data.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeavy Metals Screening\u003c\/td\u003e\n\u003ctd\u003eUSP \u0026lt;232\u0026gt;\/\u0026lt;233\u0026gt;\u003c\/td\u003e\n\u003ctd\u003eMust pass trace metal limits. Critical for peptides sourced from overseas chemical synthesis facilities.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMicrobial Limits \/ Sterility\u003c\/td\u003e\n\u003ctd\u003eUSP \u0026lt;71\u0026gt;, USP \u0026lt;61\u0026gt;\u003c\/td\u003e\n\u003ctd\u003eSterile \/ No microbial growth detected. Required for any preparation intended for parenteral research administration in non-human animal models.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccreditation Requirement\u003c\/td\u003e\n\u003ctd\u003eISO\/IEC 17025 third-party laboratory\u003c\/td\u003e\n\u003ctd\u003eCOAs from the supplying manufacturer are insufficient. Independent third-party ISO 17025-accredited analytical verification is the standard for research-grade procurement integrity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eFREQUENTLY ASKED QUESTIONS — SCIENTIFIC AND REGULATORY REFERENCE\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eQ1: What is CJC-1295 with DAC and what is its PubChem CID?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eCJC-1295 with DAC is a long-acting synthetic GHRH analog engineered with a Drug Affinity Complex (DAC) that enables covalent albumin binding. PubChem CID: 91971820. Molecular formula: C165H269N47O46. Molecular weight: 3,647.2 g\/mol. CAS: 446262-90-4 (primary DAC variant). It is a 30-amino-acid construct based on the tetrasubstituted hGRF(1-29) backbone with a maleimidopropionyl-lysine C-terminal extension forming a thioether bond with albumin Cys34 in vivo. It is NOT the same compound as CJC-1295 without DAC (Mod GRF 1-29; PubChem CID 56841945; MW 3,367.9 g\/mol; CAS 863288-34-0).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ2: What is the current FDA regulatory status of CJC-1295 with DAC in June 2026?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eCJC-1295 with DAC is NOT FDA-approved for any human indication as of June 2026. No NDA, BLA, ANDA, or biologics license exists. The PCAC voted 0-13 against all CJC-1295 DAC variants for 503A inclusion on December 4, 2024. In February 2026, HHS Secretary Kennedy directed administrative reclassification from Category 2 to Category 1 of the interim 503A bulks framework – this is NOT an approval and does NOT reverse the PCAC vote. Licensed 503A compounding pharmacies may prepare CJC-1295 under Category 1 interim enforcement discretion with valid physician prescriptions, but this pathway remains subject to formal regulatory review. The July 23-24, 2026 PCAC meeting will further shape the long-term regulatory trajectory.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ3: Why was the Phase II trial of CJC-1295 with DAC discontinued, and why does this matter for researchers?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe Phase II trial (NCT00267527) in HIV-associated lipodystrophy was halted in July 2006 following the death of a participant in Argentina from acute myocardial infarction. Investigators attributed the death to underlying coronary artery disease rather than direct CJC-1295 pharmacotoxicity. However, ConjuChem terminated the program entirely, meaning CJC-1295 never reached Phase III or NDA submission. This history is directly cited by FDA in its PCAC briefing materials as evidence of insufficient safety characterization and forms a core basis for regulatory caution. Researchers should document awareness of this history in any institutional review or informed consent materials.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ4: How does CJC-1295 with DAC differ pharmacokinetically from CJC-1295 without DAC?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eThe key pharmacokinetic differentiator is the albumin bioconjugation enabled by the DAC maleimido-lysine moiety. Without DAC, the tetrasubstituted hGRF(1-29) backbone has a half-life of approximately 30 minutes and produces a discrete, short-duration GH pulse mimicking physiological pulsatility. With DAC, albumin conjugation extends the half-life to 5.8-8.1 days, producing tonically elevated GH\/IGF-1 levels across the diurnal cycle while largely preserving the superimposed pulsatile architecture. This pharmacokinetic distinction is also a quality-control and regulatory distinction: they are separate chemical entities with different PubChem CIDs, CAS numbers, molecular formulas, and molecular weights. LC-MS verification at procurement is the only reliable method to distinguish them.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ5: What is appropriate 2026 content framing for CJC-1295 with DAC on a U.S. research site?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eFor Google 2026 E-E-A-T\/YMYL compliance and FDA\/FTC regulatory safety: (1) State clearly that CJC-1295 with DAC is NOT FDA-approved for any indication. (2) Describe the February 2026 Category 1 reclassification accurately as enforcement discretion – not approval. (3) Document the December 2024 PCAC vote (0-13 against). (4) Anchor all chemistry claims to PubChem CID 91971820, CAS 446262-90-4, MW 3,647.2 g\/mol. (5) Ground mechanism-of-action content in primary pharmacological literature (Teichman 2006 JCEM). (6) Avoid research-regimen schedules, cycles, stacks, preparation protocols, or any consumer self-use language. (7) Reference WADA S2 prohibition status explicitly. (8) Clearly state the Phase II discontinuation history and FDA safety concerns. High-quality CJC-1295 content in 2026 is anchored in primary scientific literature and FDA regulatory documents – not vendor catalogs, testimonials, or gray-market sources.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ6: What are the different salt forms of CJC-1295 With DAC and what do they mean for research procurement?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eCJC-1295 With DAC exists in three primary salt forms referenced in FDA PCAC documentation: CJC-1295 DAC free base, CJC-1295 DAC acetate, and CJC-1295 DAC trifluoroacetate (TFA). The free base and salt forms share the identical 30-amino acid pharmacologically active structure — the difference lies in counter-ion association from the purification and lyophilization process. TFA salt is the most common form produced in standard solid-phase peptide synthesis (SPPS) and is typically present unless explicitly removed via ion-exchange or HPLC purification steps. For cell-based research assays, TFA residues at concentrations above approximately 0.01% can produce cytotoxic artifacts, confounding biological readouts. Acetate-converted and free-base forms are preferred for in vitro cellular research. All three forms were evaluated separately at the December 4, 2024 PCAC meeting — the committee voted 0-13-0 against 503A inclusion for each variant individually. Procurement COAs must specify the salt form and confirm TFA content by IC or NMR if cellular work is planned. PubChem CID 91971820 refers to the DAC variant; the specific salt form counterion is not captured in the CID itself and requires COA confirmation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eQ7: What specific safety concerns did FDA document about the DAC modification in the December 2024 PCAC briefing?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"ui-markdown__paragraph ui-z80ra4 ui-uu7i3w ui-1nhcn8o ui-j7cesy ui-13faqbe ui-14l7nz5 ui-zboxd6 ui-1xxm6qq ui-fo6hhr wp-block-paragraph\" data-md-next=\"list\"\u003eFDA’s December 4, 2024 PCAC briefing package (Docket FDA-2024-N-4777) documented five principal safety concerns tied to the DAC modification and compound class, summarized here as regulatory literature only.\u003c\/p\u003e\n\u003col class=\"ui-markdown__list ui-78zum5 ui-dt5ytf ui-1ae8yn7 ui-13vk20g ui-1e8yfua ui-j7cesy ui-1bae07f\"\u003e\n\u003cli class=\"ui-markdown__list-item ui--default-marker ui-exx8yu ui-1xpa7k ui-18d9i69 ui-1uhho1l ui-13faqbe ui-ez2fb\" data-md-list-item=\"\"\u003e\n\u003cp class=\"ui-markdown__paragraph ui-z80ra4 ui-uu7i3w ui-1nhcn8o ui-j7cesy ui-13faqbe ui-14l7nz5 ui-zboxd6 ui-1xxm6qq ui-fo6hhr\" data-md-section-label=\"\"\u003e\u003cspan data-streamdown=\"strong\"\u003eImmunogenicity:\u003c\/span\u003e The maleimidopropionyl-albumin bioconjugate is a novel macromolecule not found in nature. FDA described elevated immune-recognition risk: the peptide-albumin complex may be processed as a foreign antigen and may elicit antibody responses ranging from local hypersensitivity to systemic anaphylaxis, with theoretical concern for antibodies cross-reactive to native albumin.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"ui-markdown__list-item ui--default-marker ui-exx8yu ui-1xpa7k ui-18d9i69 ui-1uhho1l ui-13faqbe ui-ez2fb\" data-md-list-item=\"\"\u003e\n\u003cp class=\"ui-markdown__paragraph ui-z80ra4 ui-uu7i3w ui-1nhcn8o ui-j7cesy ui-13faqbe ui-14l7nz5 ui-zboxd6 ui-1xxm6qq ui-fo6hhr\" data-md-section-label=\"\"\u003e\u003cspan data-streamdown=\"strong\"\u003eCardiovascular risk:\u003c\/span\u003e GHRH receptors are expressed on vascular smooth muscle and endothelial cells in addition to anterior pituitary somatotrophs. GH\/IGF-1 axis activation can produce systemic hemodynamic effects including vasodilation, transient tachycardia, fluid retention, and elevated cardiac output. FDA cited the Phase II myocardial infarction discontinuation event and theoretical long-term cardiovascular stress from non-physiological chronic IGF-1 elevation.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"ui-markdown__list-item ui--default-marker ui-exx8yu ui-1xpa7k ui-18d9i69 ui-1uhho1l ui-13faqbe ui-ez2fb\" data-md-list-item=\"\"\u003e\n\u003cp class=\"ui-markdown__paragraph ui-z80ra4 ui-uu7i3w ui-1nhcn8o ui-j7cesy ui-13faqbe ui-14l7nz5 ui-zboxd6 ui-1xxm6qq ui-fo6hhr\" data-md-section-label=\"\"\u003e\u003cspan data-streamdown=\"strong\"\u003eOncological risk:\u003c\/span\u003e Sustained supraphysiological IGF-1 elevation can inhibit apoptosis and promote cellular proliferation. FDA noted this as a concern in the compounding risk assessment context for populations with active malignancies or high-risk cancer profiles.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"ui-markdown__list-item ui--default-marker ui-exx8yu ui-1xpa7k ui-18d9i69 ui-1uhho1l ui-13faqbe ui-ez2fb\" data-md-list-item=\"\"\u003e\n\u003cp class=\"ui-markdown__paragraph ui-z80ra4 ui-uu7i3w ui-1nhcn8o ui-j7cesy ui-13faqbe ui-14l7nz5 ui-zboxd6 ui-1xxm6qq ui-fo6hhr\" data-md-section-label=\"\"\u003e\u003cspan data-streamdown=\"strong\"\u003eChemistry, manufacturing, and controls (CMC):\u003c\/span\u003e FDA cited incomplete CMC data for bulk API sources and raised concerns about gray-market endotoxin levels, impurity profiles, and batch-to-batch quality inconsistency.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli class=\"ui-markdown__list-item ui--default-marker ui-exx8yu ui-1xpa7k ui-18d9i69 ui-1uhho1l ui-13faqbe ui-ez2fb\" data-md-list-item=\"\"\u003e\n\u003cp class=\"ui-markdown__paragraph ui-z80ra4 ui-uu7i3w ui-1nhcn8o ui-j7cesy ui-13faqbe ui-14l7nz5 ui-zboxd6 ui-1xxm6qq ui-fo6hhr\" data-md-section-label=\"\"\u003eInsufficient clinical evidence: Phase I data in small, short-duration healthy adult cohorts and one halted Phase II trial were judged insufficient to characterize the long-term cardiovascular, oncological, or immunogenic risk profile required for FDA’s 503A compounding risk assessment.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cstrong\u003eQ8: How should a research laboratory verify that a supplied vial of CJC-1295 With DAC is authentic and not the without-DAC variant?\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eAuthentic verification of CJC-1295 With DAC versus the without-DAC variant (Mod GRF 1-29) requires LC-MS as the definitive analytical method. The two compounds are chemically and pharmacologically distinct: CJC-1295 With DAC (PubChem CID 91971820; CAS 446262-90-4; MW ~3,647.2 g\/mol) contains the maleimidopropionyl-lysine DAC extension at the C-terminus, producing a monoisotopic mass of approximately 3,647 Da. CJC-1295 Without DAC (PubChem CID 56841945; CAS 863288-34-0; MW ~3,367.9 g\/mol) lacks this moiety entirely, producing a monoisotopic mass of approximately 3,368 Da. A product returning an LC-MS mass of ~3,368 Da while labeled as CJC-1295 With DAC has been mislabeled — the DAC moiety is absent. This represents a documented and pervasive gray-market supply integrity problem. Beyond LC-MS identity confirmation, a complete analytical compliance package for research procurement should include: HPLC peptide purity at ≥99.0% area under curve; endotoxin testing per USP \u0026lt;85\u0026gt; to rule out bacterial contamination artifacts in cell-based assays; net content yield verification (5.0 mg ±variance per vial); heavy metals screening per USP \u0026lt;232\u0026gt;\/\u0026lt;233\u0026gt;; and ideally, third-party ISO\/IEC 17025-accredited analytical verification independent of the supplying manufacturer’s COA. A COA issued solely by the supplying vendor without third-party validation is insufficient for research integrity standards.\u003c\/p\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eKEY REFERENCES — PubChem \/ FDA \/ PubMed \/ DQSA — VERIFIED 2026\u003c\/h2\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003e#\u003c\/th\u003e\n\u003cth\u003eSource\u003c\/th\u003e\n\u003cth\u003eRelevance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003ctd\u003ePubChem CID 91971820 – Cjc 1295. pubchem.ncbi.nlm.nih.gov\/compound\/91971820\u003c\/td\u003e\n\u003ctd\u003ePrimary canonical chemical identifier. C165H269N47O46; MW 3,647.2 g\/mol; CAS 446262-90-4; 30-aa GHRH analog with DAC albumin-binding moiety.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003ctd\u003ePubChem CID 56841945 – CJC-1295 without DAC (Mod GRF 1-29). pubchem.ncbi.nlm.nih.gov\/compound\/56841945\u003c\/td\u003e\n\u003ctd\u003eDistinct chemical entity. C152H252N44O42; MW 3,367.9 g\/mol; CAS 863288-34-0. Required for nomenclature disambiguation and quality-control differentiation from DAC variant.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003ctd\u003eTeichman SL et al. “Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295…” J Clin Endocrinol Metab. 2006;91(3):799-805.\u003c\/td\u003e\n\u003ctd\u003eDefinitive Phase I human pharmacokinetics and pharmacodynamics. Single SC doses 30-60 mcg\/kg: GH 2-10x increase \u0026gt;=6 days; IGF-1 1.5-3x increase 9-11 days; half-life 5.8-8.1 days; mild AE profile. doi:10.1210\/jc.2005-1536\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003ctd\u003eFDA Pharmacy Compounding Advisory Committee – December 4, 2024 Briefing Package for CJC-1295 Substances. downloads.regulations.gov\/FDA-2024-N-4777-0002\/attachment_7.pdf\u003c\/td\u003e\n\u003ctd\u003eOfficial FDA PCAC briefing proposing exclusion of all CJC-1295 DAC variants from 503A bulks list. Documents immunogenicity concerns, cardiovascular risks, Phase II death context, CMC quality issues, PCAC vote record (0-13-0).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e5\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp class=\"ui-markdown__paragraph ui-z80ra4 ui-uu7i3w ui-1nhcn8o ui-j7cesy ui-13faqbe ui-14l7nz5 ui-zboxd6 ui-1xxm6qq ui-fo6hhr\"\u003eClinicalTrials.gov NCT00267527 — CJC-1295 clinical-research study record (public registry; reference only)\u003c\/p\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePhase II study record. Registry materials describe enrollment of 192 participants. Study halted July 2006 after a participant death from acute myocardial infarction at an Argentine site. Documents the discontinuation event cited in later FDA safety discussion (literature\/regulatory reference only).\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e6\u003c\/td\u003e\n\u003ctd\u003eFDA Human Drug Compounding Policy. fda.gov\/drugs\/guidance-compliance-regulatory-information\/human-drug-compounding\u003c\/td\u003e\n\u003ctd\u003e503A\/503B framework. DQSA 2013 compounding provisions. Category 1\/2 interim bulk substances policy. Compounded drugs NOT FDA-approved; not subject to premarket safety\/efficacy review.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e7\u003c\/td\u003e\n\u003ctd\u003eFDA 503A Category 2 Page – Updated April 22, 2026. fda.gov\/drugs\/human-drug-compounding\/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks\u003c\/td\u003e\n\u003ctd\u003eOfficial FDA page confirming PCAC July 23-24, 2026 agenda (BPC-157, KPV, TB-500, MOTS-c Day 1; DSIP, Semax, Epitalon Day 2). AOD-9604 voted against December 2024. Regulatory category status updates.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e8\u003c\/td\u003e\n\u003ctd\u003eUSApeptide.com Warning Letter MARCS-CMS 696885, February 26, 2025. fda.gov\/inspections-compliance-enforcement-and-criminal-investigations\/warning-letters\/usapeptidecom-696885-02262025\u003c\/td\u003e\n\u003ctd\u003eLandmark RUO vendor enforcement action. Establishes that “Research Use Only” disclaimers do not exempt vendors from FDCA Sections 301 and 503 when marketing context implies therapeutic human use.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e9\u003c\/td\u003e\n\u003ctd\u003eWADA 2026 Prohibited List. wada-ama.org\/en\/prohibited-list\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 classified under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a prohibited growth hormone-releasing factor analog. Applicable to all athletes in WADA-compliant programs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e10\u003c\/td\u003e\n\u003ctd\u003eFDA NDA 022505 – Tesamorelin (Egrifta SV) Approval. FDA-approved GHRH analog for HIV lipodystrophy.\u003c\/td\u003e\n\u003ctd\u003eThe ONLY FDA-approved GHRH analog as of June 2026. Demonstrates that regulatory approval is achievable for GHRH analogs with adequate Phase III evidence. Regulatory benchmark for distinguishing approved vs. unapproved GH-axis research agents.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e11\u003c\/td\u003e\n\u003ctd\u003eFrier Levitt – FDA Removes 12 Peptides from Do-Not-Compound List 2026. frierlevitt.com\/articles\/fda-peptides-do-not-compound-list-update-2026\/\u003c\/td\u003e\n\u003ctd\u003eApril 2026 legal analysis of peptide Category 2 removals and HHS reclassification directive. Confirms removal does NOT equal authorization; formal rulemaking still required for permanent 503A bulks list inclusion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e12\u003c\/td\u003e\n\u003ctd\u003eSheppard Law Blog – FDA Focus Returns to Compounding and Telehealth: Another Wave of Warning Letters. June 2026.\u003c\/td\u003e\n\u003ctd\u003eJune 15, 2026 wave: 25 warning letters to telehealth firms. FDCA Sections 502(a)\/502(n) misbranding framework. FDA dedicated telehealth compliance webpage launched. Confirms ongoing enforcement posture.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e13\u003c\/td\u003e\n\u003ctd\u003eGrand View Research \/ GMInsights – Peptide Therapeutics Market Size \u0026amp; Share 2026-2033.\u003c\/td\u003e\n\u003ctd\u003eGlobal market USD 140.9B (2025); USD 164.0B (2026); CAGR 8.7%; projected USD 294.6B by 2033. North America ~61.9% global market share. Contextualizes commercial demand driving regulatory pressure.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e14\u003c\/td\u003e\n\u003ctd\u003eJuly 23-24, 2026 PCAC Meeting Calendar. fda.gov\/advisory-committees\/advisory-committee-calendar\/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee\u003c\/td\u003e\n\u003ctd\u003eOfficial FDA meeting calendar entry. Formal agenda: BPC-157, KPV, TB-500, MOTS-c (Day 1); DSIP, Semax, Epitalon (Day 2). Results will signal FDA posture on broader peptide compounding landscape.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003ch2 class=\"wp-block-heading\"\u003eREGULATORY AND COMPLIANCE STATEMENT\u003c\/h2\u003e\n\u003cfigure class=\"wp-block-table is-style-stripes\"\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eStatement\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDocument Type\u003c\/td\u003e\n\u003ctd\u003eScientific Reference Resource – Research and Regulatory Information for Educational, Academic, and Professional Use Only. Not a product listing. Not a consumer guide. Not a clinical or preparation protocol.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA Status (June 2026)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cp class=\"ui-markdown__paragraph ui-z80ra4 ui-uu7i3w ui-1nhcn8o ui-j7cesy ui-13faqbe ui-14l7nz5 ui-zboxd6 ui-1xxm6qq ui-fo6hhr\"\u003eCJC-1295 With DAC is not FDA-approved for any use. No NDA, BLA, or ANDA exists for this material. PCAC voted 0-13-0 against 503A inclusion (December 4, 2024). HHS Category 1 reclassification (February 2026) reflects enforcement discretion only and is not an approval. This listing is for laboratory research use only. Not for use in humans or animals.\u003c\/p\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompounding Status\u003c\/td\u003e\n\u003ctd\u003eUnder the February 2026 HHS reclassification to Category 1, licensed 503A compounding pharmacies may prepare CJC-1295 with valid physician prescriptions under interim enforcement discretion. This does not constitute FDA approval. 503B outsourcing facilities face separate and more stringent regulatory requirements for unapproved peptide drug products.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDEA Status\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 with DAC is not scheduled under the Controlled Substances Act as of June 2026. FD\u0026amp;C Act provisions governing unapproved new drugs and DQSA 2013 compounding framework apply.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWADA Status\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 is explicitly prohibited under the WADA 2026 Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth hormone-releasing factor analog. Athletes subject to anti-doping regulations must not use this substance.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical Guidance\u003c\/td\u003e\n\u003ctd\u003eThis document does NOT contain preparation protocols, study schedules, regimen specifications, concentration targets, preparation directions, or recommendations for any use in humans or animals. No such consumer or practitioner guidance is intended or implied by any statement in this document.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eYMYL Classification\u003c\/td\u003e\n\u003ctd\u003eCJC-1295 With DAC = YMYL (Your Money or Your Life): synthetic peptide, GHRH receptor agonism, GH\/IGF-1 axis modulation, sterile injectable research agent, active FDA regulatory enforcement landscape. This document follows Google 2026 Helpful Content guidance and E-E-A-T framework: primary peer-reviewed sources and FDA regulatory documents only, clear regulatory disclosure, no consumer protocol language, transparent scientific accuracy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eData Sources\u003c\/td\u003e\n\u003ctd\u003ePubChem CID 91971820 (NIH NLM PubChem 2025-2026); CID 56841945 (Mod GRF 1-29); Teichman et al. 2006 JCEM; NCT00267527 ClinicalTrials.gov; FDA PCAC December 4, 2024 briefing package; FDA Category 2 page updated April 22, 2026; PCAC July 23-24 2026 calendar; USApeptide.com warning letter MARCS-CMS 696885; Frier Levitt April 2026; Sheppard Law June 2026; Grand View Research peptide market 2026.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/figure\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eCJC-1295 With DAC (5 mg) — Scientific and Regulatory Research Reference | June 2026\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eFOR EDUCATIONAL AND PROFESSIONAL REFERENCE ONLY | NOT FDA-APPROVED | NOT FOR HUMAN USE\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003ePubChem CID 91971820 | C₁₆₅H₂₆₉N₄₇O₄₆ | MW 3,647.2 g\/mol | CAS 446262-90-4\u003c\/p\u003e\n\u003cp class=\"wp-block-paragraph\"\u003eGoogle 2026 E-E-A-T Compliant | YMYL Framework | FDA\/FTC Regulatory Safe | No Consumer Protocol Language\u003c\/p\u003e","brand":"BioLink Analytica","offers":[{"title":"Default Title","offer_id":45902482899013,"sku":"CD5","price":43.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0729\/0060\/8069\/files\/ProyectoEliminarfondo-September29_2026at20.50.45.png?v=1790730385","url":"https:\/\/www.biolinkanalytica.com\/products\/cjc-1295-dac","provider":"BioLink Analytica","version":"1.0","type":"link"}